AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00861562
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 01 pill at every 8 hours for 5 days, with the exact same appearance as the other intervention.
Trial: NCT01504126
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo standard chemotherapy
Trial: NCT03507387
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1ml 0.9% normal saline intramuscular injection will be given into the gluteus maximus muscle before anesthesia and after the subarachnoid injection is completed.
Trial: NCT03261427
Drug: YNP-1807 330Mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 330 mg oral administered (QD)
Trial: NCT02127021
Drug: Norzyme® 40000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A kind of pancreatic enzyme supplement containing lipase: 40,000 FIP, amylase: 25,000 FIP, and protease: 1,500 FIP Single capsule of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal
Trial: NCT02127021
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single capsule of placebo drug with the same appearance of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal.
Trial: NCT00351052
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle control (placebo) bid.
Trial: NCT00683462
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00683462
Drug: AZD3480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules 5 mg/day (once a day) for 2 weeks
Trial: NCT00683462
Drug: AZD3480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules 50 mg/day (once a day) for 2 weeks
Trial: NCT01474252
Drug: RSI
RxNorm normalized name: Lorsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All medications are administered only one dose before intubation~Anesthetics:~Propofol 2-2.5 mg/kg Thiopental 3-5mg/kg Etomidate 1-2mg/kg~Neuromuscular blocking agents:~Succinylcholine 1-1.5mg/kg Rocuronium 0.9mg/kg~Opioid:~Fentanyl 1-2ug/kg
Trial: NCT03085797
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a clear to opalescent, colorless sterile solution for SC injection in a single-use, safety syringe.
Trial: NCT02415907
Drug: [ethyl-1-14C]-idalopirdine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg/2.40 MBq Lu AF67708 (\[ethyl-1-14C\]-idalopirdine) in one capsule for oral administration, single dose
Trial: NCT02415907
Drug: [benzyl-7-14C]-idalopirdine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg/2.40 MBq Lu AF67709 (\[benzyl-7-14C\]-idalopirdine) in one capsule for oral administration, single dose
Trial: NCT02147015
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02147015
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02147015
Drug: Inhaled corticosteroid (ICS)
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02147015
Drug: Long-Acting Muscarinic Antagonists(LAMA)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02147015
Drug: Short-acting beta2-agonist (SABA)
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01837823
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All subjects will receive rosuvastatin 40mg/day for 8-12 weeks
Trial: NCT02291458
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 gram placebo / day for 6 weeks
Trial: NCT02147015
Drug: long-acting beta2-agonist (LABA)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02101957
Drug: RP103
RxNorm normalized name: Cysteamine
DrugBank: Cysteamine (DB00847)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02054104
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg by mouth (PO) twice a day (BID) for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each treatment cycle.
Trial: NCT02054104
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg by mouth (PO) twice a day (BID) for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each treatment cycle.
Trial: NCT02101957
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00867815
Drug: Diagnostic procedures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will not receive any study drug in this study. The patients will have ophthalmological (eye) examinations, blood work and will complete an interview
Trial: NCT00120419
Drug: mycophenol mofetil (MMF, Cellcept®) 500 mg BID
RxNorm normalized name: mycophenolate mofetil 500 MG
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01801228
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00752206
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Agent
Trial: NCT01046838
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet 3 times daily for 9 weeks
Trial: NCT01497288
Drug: INFS (Intranasal Fentanyl Spray)
RxNorm normalized name: fentanyl Mucosal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal Fentanyl Spray
Trial: NCT00004554
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02586649
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a non-active inhalation capsule .
Trial: NCT00710580
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ placebo injections for ABT-874 and etanercept
Trial: NCT02896413
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline infusion
Trial: NCT04374942
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill (same formula as Hydroxychloroquine without active ingredient) taken once daily, for three months.
Trial: NCT00001213
Drug: Cysteamine
RxNorm normalized name: Cysteamine
DrugBank: Cysteamine (DB00847)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03374852
Drug: mFOLFIRNOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFIRNOX (given immediately after CPI-613 administration):
Trial: NCT00373113
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1250 mg/m\^2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
Trial: NCT03736772
Drug: LY3090106
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03736772
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT00674713
Drug: Physiological saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04335136
Drug: Physiological saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with placebo intravenously twice daily (BID).
Trial: NCT00787618
Drug: 50 mg Proellex
RxNorm normalized name: guaiacolsulfonate / hydrocodone bitartrate Oral Solution [Prolex DH]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT00587496
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lactose placebo capsule, six per day for 30 days
Trial: NCT01683565
Drug: LCPUFA oil supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5mL per day for 90 days~Daily Dose: EPA (338mg) + DHA (225mg) + GLA (83mg) + OA (200mg)
Trial: NCT00965562
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg per day for 4 menstrual cycles. For the fifth menstrual cycle, all women will receive calcium. Women on Fluoxetine will continue taking it in addition to 1200mg of calcium.
Trial: NCT00965562
Drug: Calcium
RxNorm normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg of calcium to be taken for 5 menstrual cycles.
Trial: NCT02597478
Drug: Fentanyl Sublingual Spray
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose Fentanyl Goup: 15-25% of the morphine equivalent daily dose (MEDD) sprayed into mouth and under tongue one hour after first Shuttle Walk Test.~High-Dose Fentanyl Group: 35-45% of the morphine equivalent daily dose (MEDD) sprayed into mouth and under tongue one hour after first Shuttle Walk Test.
Trial: NCT01329562
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo tablet matching Treximet for oral administration.
Trial: NCT00002738
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03005015
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00352664
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet once a day by mouth for one 7 day cycle. After evaluation on day 8, all participants offered donepezil every day for 7 days.
Trial: NCT05532306
Drug: Copegus® 200 mg film coated tablet (2*200mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an immediate release film-coated tablet containing 200 mg Ribavirin
Trial: NCT02038699
Drug: ONC201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONC201 capsules will be administered orally once every three weeks with flat dosing. Dosage will be given according to a modified Fibonacci sequence with the anticipated starting dose being 125 mg.
Trial: NCT03868059
Drug: LPCN 1021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPCN 1021 is gelatin capsule product provided as 112.5 mg testosterone undecanoate per capsule.
Trial: NCT01970098
Drug: KPS-0373, High dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28 weeks
Trial: NCT01970098
Drug: KPS-0373, Low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28 weeks
Trial: NCT01970098
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28 weeks
Trial: NCT04509661
Drug: LABA/LAMA or Placebo inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled LABA/LAMA for one year.
Trial: NCT01719497
Drug: [C-11]OMAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET radioligand
Trial: NCT01305577
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate buffered saline placebo for injection
Trial: NCT03120351
Drug: Lidoderm 5 % Topical Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive Lidoderm topical 5% lidocaine patches. Those will be placed to affected area up to three patches as needed for pain 12 hours on and 12 hours off
Trial: NCT03120351
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2) Group II: Patients will receive placebo patches. Those will be placed to affected area at dose up to three patches as needed for pain 12 hours on and 12 hours off
Trial: NCT01203982
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 5mg/day for one year
Trial: NCT01203982
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 40mg/day for one year
Trial: NCT04106206
Drug: LY3372689
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT04106206
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00241839
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule (matched in appearance for Allopurinol and labeled 300mg) was given for 8-10 weeks compared to the Allopurinol group after initial baseline testing. After two weeks on the placebo, a serum uric acid level was obtained. If the uric acid level was greater than 5.5, the placebo dosage was increased to 600mg (two 300 mg capsules)for the duration of the study, 6-8 weeks.
Trial: NCT00241839
Drug: Chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 25 mg was given daily for 5 weeks before baseline visit for testing and continued through out the study.
Trial: NCT02231931
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: single dose, fasted
Trial: NCT02231931
Drug: Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fasted
Trial: NCT03066947
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low dose pre-treatment to reduce regulatory T cells
Trial: NCT04420104
Drug: iv analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv contromal
Trial: NCT00271453
Drug: Durogesic® (fentanyl transdermal drug delivery system)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01963078
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01998165
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After intubation, continuous intravenous infusion of remifentanil (0.25 µg/kg/min) is started, while anesthesia is maintained with inhaled or intravenous anesthetics. In cases where sedation by general anesthetics and analgesia by lidocaine does not seem to provide a sufficient means of analgesia at the time of intubation, remifentanil may be used, beginning before intubation. The rate of infusion may be adjusted while monitoring the subject's general condition in 25% to 100% increments or in 25% to 50% decrements every 2 to 5 minutes, but should not exceed 1.3 µg/kg/min.
Trial: NCT00704119
Drug: RhuDex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Treatment A.1: 31.65 mg RhuDex® once N=12~* Treatment A.2: 63.33 mg RhuDex® once N=12~* Treatment A.3: 126.63 mg RhuDex® once N=12~* Treatment A.4: 253.26 mg RhuDex® once N=12~* Treatment B.1: 31.65 mg RhuDex® once N=12~* Treatment B.2: selected dose of RhuDex® once N=12~* Treatment C: selected dose of RhuDex® once N=12~* Treatment D: selected dose of RhuDex® twice daily for 6 days N=12
Trial: NCT04462614
Drug: Decrease per-dialytic heparin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Week 1: maintenance's dose stop Week 2: 50% drop in the loading dose Week 3: complete cessation of heparin therapy during the session.
Trial: NCT03048578
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Saline Solution
Trial: NCT00390676
Drug: ADH -1 and capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04487886
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo to match duvelisib will be taken orally twice per day for 14 days.
Trial: NCT02625909
Drug: SOF/VEL for 6 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm A (6 weeks short treatment duration).
Trial: NCT02625909
Drug: SOF/VEL for 12 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm B (12 weeks standard treatment duration).
Trial: NCT01103193
Drug: remifentanil injected
RxNorm normalized name: remifentanil Injection
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mixture of 60% nitrous oxide and 40% oxygen is administered through a face mask. In the first group the patient receives a constant concentration of sevoflurane. In this group the remifentanil concentration will be injected via an intravenous line in a step up protocol.
Trial: NCT03001817
Drug: Placebo (for K-877)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03001817
Drug: Placebo (for Fenofibrate)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03855059
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This will be a saline solution of given IV or perineural.
Trial: NCT00925457
Drug: Current proton pump inhibitor (PPI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current PPI and not current dapoxetine
Trial: NCT00379821
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 30 mg/kg once a day for 3 days, 200 mg/5cc suspension
Trial: NCT02284243
Drug: Intranasal Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01283282
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo PO qday for 6 weeks
Trial: NCT01339052
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02618096
Drug: Dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01704482
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00083226
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01148992
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0mg
Trial: NCT00566696
Drug: Thioplex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
Trial: NCT00909857
Drug: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral administration of one tablet SH T00658ID for 28 days per cycle in the respective treatment period; no tablet-free interval
Trial: NCT00909857
Drug: Ethinyl estradiol, Levonorgestrel (Miranova)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral administration of one tablet for 28 days per cycle in the respective treatment period; no tablet-free interval
Trial: NCT00566696
Drug: Rituxan™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
Trial: NCT00566696
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
Trial: NCT03369262
Drug: OBE022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03369262
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01847027
Drug: NutraStem
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress.~Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress.
Trial: NCT01847027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress.
Trial: NCT02872935
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1ml of normal saline will be given intravenously with the administration of the spinal dose
Trial: NCT00082797
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00082797
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02196662
Drug: IBD98-M:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single adiministration
Trial: NCT02196662
Drug: IBD98-M without HA
RxNorm normalized name: M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single adiministration
Trial: NCT03414931
Drug: Placebo - Cap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of placebo as a comparator
Trial: NCT02111304
Drug: iOWH032
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03734913
Drug: ZSP1602
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP1602 capsules for oral administration
Trial: NCT00532610
Drug: GSK189075
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03198624
Drug: HTL0018318
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A single dose Part B five doses
Trial: NCT03198624
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B only
Trial: NCT02331277
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo